journal
MENU ▼
Read by QxMD icon Read
search

Hematology/oncology Clinics of North America

journal
https://www.readbyqxmd.com/read/29157623/castleman-disease
#1
EDITORIAL
Frits van Rhee, Nikhil C Munshi
No abstract text is available yet for this article.
February 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29157622/treatment-of-idiopathic-castleman-disease
#2
REVIEW
Frits van Rhee, Amy Greenway, Katie Stone
Important progress has been made in the treatment of idiopathic multicentric Castleman disease (iMCD) with the introduction of interleukin-6 targeting monoclonal antibodies. This article describes the clinical results obtained with different treatment modalities and uses this evidence to provide treatment guidelines for the practicing clinician. Much is still to be learned about the pathophysiology of iMCD and further research is urgently needed to develop novel and curative treatment approaches for all patients...
February 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29157621/treatment-of-kaposi-sarcoma-herpesvirus-associated-multicentric-castleman-disease
#3
REVIEW
Kathryn Lurain, Robert Yarchoan, Thomas S Uldrick
Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a rare, polyclonal lymphoproliferative disorder characterized by flares of inflammatory symptoms, edema, cytopenias, lymphadenopathy, and splenomegaly. Diagnosis requires a lymph node biopsy. Pathogenesis is related to dysregulated inflammatory cytokines, including human and viral interleukin-6. Rituximab alone or in combination with chemotherapy, such as liposomal doxorubicin, has led to an overall survival of over 90% at 5 years...
February 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29157620/unicentric-castleman-disease
#4
REVIEW
Raymond S M Wong
Unicentric Castleman disease (UCD) is a rare lymphoproliferative disorder that manifests typically as proliferation of a single lymph node or region of lymph nodes. Histologically, hyaline vascular variant is found in a majority of UCDs. UCD commonly presents in younger patient populations. Patients with UCD may be asymptomatic or present with symptoms related to mass effects on surrounding structures. It is difficult to achieve a definitive diagnosis by imaging alone. Histologic examination of the lesion remains the gold standard for diagnosis...
February 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29157619/diagnosis-of-castleman-disease
#5
REVIEW
Raphaƫl Szalat, Nikhil C Munshi
Castleman disease (CD) is a rare and heterogenous group of disorders sharing in common an abnormal lymph node pathology. CD comprises distinct subtypes with different prognoses. Unicentric CD and multicentric CD are featured by specific systemic manifestations and may be associated with Kaposi sarcoma, non-Hodgkin and Hodgkin lymphoma, and POEMS syndrome. Multicentric CD is classically associated with systemic symptoms and poorer prognosis. In this article, the authors review how to diagnose the disease, keeping in context the clinical findings, biochemical changes and complications associated with CD...
February 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29157618/pathology-of-castleman-disease
#6
REVIEW
David Wu, Megan S Lim, Elaine S Jaffe
The term Castleman disease encompasses several distinct lymphoproliferative disorders with different underlying disease pathogenesis, and clinical outcomes. It includes unicentric and multicentric diseases with limited versus significant systemic symptoms, respectively. Importantly, the histopathologic features encountered in the various forms of Castleman disease are diverse, and for the most part, lack specificity, because they are seen to varying degrees in different clinical variants of Castleman disease, and in reactive (autoimmune/infectious) and malignant (lymphoma) contexts...
February 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29157617/the-role-of-interleukin-6-in-castleman-disease
#7
REVIEW
Kazuyuki Yoshizaki, Shinichi Murayama, Hiroki Ito, Tomohiro Koga
Since its discovery, improvements in treating Castleman disease and its variants have centered on interleukin-6 (IL-6). IL-6 was discovered from T-cell factors (BCDF or BSF-2), which induced B-cell maturation. Most symptoms of the plasma cell variant of Castleman disease are linked to the hyperfunction of IL-6, constitutively produced in the affected lymph nodes (1989), suggesting IL-6 is key in the pathogenesis of multicentric Castleman disease (MCD). The results of several studies have shown that most MCD symptoms and abnormal laboratory results are improved by anti-IL-6 MCD treatments, such as tocilizumab, a humanized anti-IL-6 receptor antibody, and siltuximab, an anti-IL-6 antibody...
February 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29157616/the-peripheral-neuropathies-of-poems-syndrome-and-castleman-disease
#8
REVIEW
Michelle L Mauermann
Polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes (POEMS) syndrome is a rare paraneoplastic disorder. The polyneuropathy can be the presenting symptom and is typically a painful, motor-predominant polyradiculoneuropathy often mimicking chronic inflammatory demyelinating polyradiculoneuropathy. The presence of a lambda monoclonal protein, elevated vascular endothelial growth factor, systemic features, and treatment resistance are clues to the diagnosis. Castleman disease (CD) is seen in a subset of these patients, and when present the neuropathy is similar but less severe...
February 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29157615/poems-syndrome-therapeutic-options
#9
REVIEW
Arnaud Jaccard
Treatment of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome should be directed at the underlying plasma cell clone with risk-adapted therapy based on the extent of the plasma cell disorder. Radiation therapy is effective for patients with a localized presentation, without bone marrow involvement, and 1 to 3 bone lesions. Patients with disseminated disease should receive, preferably, high-dose chemotherapy with peripheral blood transplantation. Low-dose melphalan and dexamethasone or new agents used in myeloma are also effective...
February 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29157614/poems-syndrome-diagnosis-and-investigative-work-up
#10
REVIEW
Angela Dispenzieri, Taxiarchis Kourelis, Francis Buadi
POEMS syndrome is a rare paraneoplastic syndrome secondary to a plasma cell dyscrasia. Recognition of a combination of peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, skin changes, papilledema, extravascular volume overload, sclerotic bone lesions, thrombocytosis, and Castleman disease is the first step in managing the disease. Increased blood levels of vascular endothelial growth factor are usually confirmatory. This rare disorder should not be missed, especially if the patient has a putative diagnosis of chronic inflammatory polyradiculoneuropathy, a lambda restricted monoclonal gammopathy, and thrombocytosis, and is not responding as expected to immunomodulatory therapy commonly used for chronic inflammatory polyradiculoneuropathy...
February 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29157613/castleman-disease-pathogenesis
#11
REVIEW
David C Fajgenbaum, Dustin Shilling
Castleman disease (CD) describes a group of heterogeneous disorders with common lymph node histopathologic features, including atrophic or hyperplastic germinal centers, prominent follicular dendritic cells, hypervascularization, polyclonal lymphoproliferation, and/or polytypic plasmacytosis. The cause and pathogenesis of the four subtypes of CD (unicentric CD; human herpesvirus-8-associated multicentric CD; polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes [POEMS]-associated multicentric CD; and idiopathic multicentric CD) vary considerably...
February 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29157612/tafro-syndrome
#12
REVIEW
Takuro Igawa, Yasuharu Sato
TAFRO syndrome is a newly recognized variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly (O). Thrombocytopenia and severe anasarca accompanied by relatively low serum immunoglobulin levels are characteristic clinical findings of TAFRO syndrome that are not present in iMCD-not otherwise specified (iMCD-NOS). Lymph node biopsy is recommended to exclude other diseases and to diagnose TAFRO syndrome, which reveals characteristic histopathological findings similar to hyaline vascular-type CD...
February 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29157611/epidemiology-of-castleman-disease
#13
REVIEW
David Simpson
Castleman disease is a rare entity, including unicentric Castleman disease (UCD), human herpesvirus-8 plus Castleman disease (HHV-8+MCD), and idiopathic multicentric Castleman disease (iMCD). UCD is the most common at 16 per million person years and occurs at every age. HHV-8+MCD incidence varies widely, mostly affecting human immunodeficiency virus-positive men. iMCD is likely a more heterogeneous disease with an estimated incidence of 5 per million person years. Improved definitions should improve understanding of the epidemiology of Castleman disease and its subtypes...
February 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29078935/hematology-oncology-emergencies
#14
EDITORIAL
John C Perkins, Jonathan E Davis
No abstract text is available yet for this article.
December 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29078934/chemotherapeutic-medications-and-their-emergent-complications
#15
REVIEW
Janet S Young, Jennifer W Simmons
Patients with complications of chemotherapy, either acute or chronic, are frequently encountered in the emergency department (ED). Some patients present with complaints immediately after chemotherapy administration, whereas others may show subtle, secondary signs or may have no signs or symptoms of chemotoxicity. An increased index of suspicion prompts early recognition, diagnosis, and prevention of further iatrogenic injury. This article reviews characteristic hypersensitivity reactions, typical organ system dysfunction, and treatment strategies for adult patients who present to the ED with complications after chemotherapy...
December 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29078933/neutropenic-fever
#16
REVIEW
Lindsey White, Michael Ybarra
Fever is a common presenting complaint among adult or pediatric patients in the emergency department setting. Although fever in healthy individuals does not necessarily indicate severe illness, fever in patients with neutropenia may herald a life-threatening infection. Therefore, prompt recognition of patients with neutropenic fever is imperative. Serious bacterial illness is a significant cause of morbidity and mortality for neutropenic patients. Neutropenic fever should trigger the initiation of a rapid work-up and the administration of empiric systemic antibiotic therapy to attenuate or avoid the progression along the spectrum of sepsis, severe sepsis, septic shock syndrome, and death...
December 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29078932/pediatric-oncologic-emergencies
#17
REVIEW
Melanie K Prusakowski, Daniel Cannone
The overall prognosis for most pediatric cancers is good. Mortality for all childhood cancers combined is approximately half what it was in 1975, and the survival rates of many malignancies continue to improve. However, the incidence of childhood cancer is significant and the related emergencies that develop acutely carry significant morbidity and mortality. Emergency providers who can identify and manage oncologic emergencies can contribute significantly to an improved prognosis. Effective care of pediatric malignancies requires an age-appropriate approach to patients and compassionate understanding of family dynamics...
December 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29078931/oncologic-metabolic-emergencies
#18
REVIEW
Jonathan Wagner, Sanjay Arora
Cancer and its therapies may lead to several metabolic emergencies that emergency providers (EPs) should be well-versed in identifying and managing. With prompt recognition and treatment initiation in the emergency department, lives can be saved and quality of life maintained. Most oncologic metabolic emergencies occur in advanced cancer states, but some follow initiation of treatment or may be the presenting syndrome that leads to the cancer diagnosis. This article reviews the 2 most emergent oncologic metabolic diagnoses: tumor lysis syndrome and hypercalcemia of malignancy...
December 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29078930/oncologic-mechanical-emergencies
#19
REVIEW
Umar A Khan, Carl B Shanholtz, Michael T McCurdy
Prevalence of cancer and its various related complications continues to rise. Increasingly these life-threatening complications are initially managed in the emergency department, making a prompt and accurate diagnosis crucial to effectively institute the proper treatment and establish goals of care. The following oncologic emergencies are reviewed in this article: pericardial tamponade, superior vena cava syndrome, brain metastasis, malignant spinal cord compression, and hyperviscosity syndrome.
December 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29078929/blood-product-transfusions-and-reactions
#20
REVIEW
Jessica L Osterman, Sanjay Arora
Blood product transfusions are an essential component of the practice of emergency medicine. From acute traumatic hemorrhage to chronic blood loss necessitating transfusion for symptomatic anemia, familiarity with individual blood products and their indications for transfusion is an essential tool for every emergency physician (EP). Although the focus of this article is primarily on the transfusion of red blood cells, many of the concepts are applicable to the transfusion of all blood products. EPs must be fully familiar with both the individual blood components and the potential reactions and complications of these transfusions...
December 2017: Hematology/oncology Clinics of North America
journal
journal
29616
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"